Accession Number: | 0001375151-20-000116 |
Date: | 2020-06-25 |
Issuer: | ZOGENIX, INC. (ZGNX) |
Original Submission Date: |
FARFEL GAIL M
C/O ZOGENIX, INC.
5959 HORTON STREET, SUITE 500
EMERYVILLE, CA 94608
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-06-25 | M | 8,750 | a | $0.00 | 14,223 | direct | ||
COMMON STOCK | 2020-06-25 | F | 3,044 | d | $0.00 | 11,179 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
RESTRICTED STOCK UNITS | 0.0 | 2020-06-25 | deemed execution date | M | 8,750 (d) | common stock 8,750 | $0.00 | 0 | direct |
ID | footnote |
---|---|
f1 | the restricted stock units (rsus) were granted on march 14, 2017, with 100% of the rsus to vest upon approval of the company's new drug application (nda) by the u.s. food and drug administration for fintepla. the nda was approved on june 25, 2020. |
f2 | includes 425 shares acquired under the company's employee stock purchase plan since the last section 16 filing by the reporting person. |
f3 | represents shares withheld to satisfy tax withholding obligations in connection with the vesting of shares of rsus described in footnote 1. |
f4 | each rsu represents a contingent right to receive one share of zgnx common stock. |
f5 | not applicable. |